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Abstract
Human papillomavirus (HPV) is widespread and can cause latent infection in basal cells, with low
HPV DNA copy-number insufficient for transmission of infection; can cause subclinical infection
that is active but without clinical signs; or can cause clinical infection leading to benign, potentially
malignant or malignant lesions. The HPV cycle is influenced by the stage of maturation of the
infected keratinocytes, and the production of virions is restricted to the post-mitotic suprabasal
epithelial cells where all the virus genes are expressed.
Low-risk HPV genotypes are associated with the development of benign oral lesions, whereas high-
risk HPV genotypes are implicated in the development of malignant epithelial neoplasms. The rôle
of high-risk HPV as a causative agent in epithelial malignancy is different at different anatomical sites:
it is almost invariably implicated in squamous cell carcinoma of the uterine cervix, fairly frequently
implicated in squamous cell carcinoma of the oropharynx, and it is seldom implicated in squamous
cell carcinoma of the mouth.
Introduction
Human papilloma viruses (HPV) are members of the pap-
illomaviridae family that infect epithelial cells exclusively.
After gaining entry into the cells of the epithelial basal
layer, replication of the virus occurs in the nuclei of the
infected cells, and the production of mature virions occurs
in the suprabasal epithelial cell layers [1]. HPV infection
is highly transmissible, has a variable incubation period
that can culminate in latent infection with low HPV DNA
copy-number in basal cells insufficient to support trans-
missibility; in subclinical infection that is active but with-
out clinical signs; or in clinical infection leading to
benign, potentially malignant or malignant epithelial
lesions. Many of these manifestations of HPV infection
can undergo spontaneous resolution [2].
HPV infection is the most common of all sexually trans-
mitted diseases. It is estimated that two thirds of those
who have had sexual contact with HPV-infected persons,
will become infected [3]. Oral HPV infection can be
acquired by oral-genital contact, by mouth-to-mouth con-
tact, or possibly by autoinoculation [4,5]; and in infants
by mother-to-child transmission [6,7]. How HPV infec-
tion of the upper respiratory tract occurs is not clear, but
it may be by mucous carriage of virally infected squames
from the mouth, or from the mouth of another person to
the oropharynx and larynx [8].
The clinical manifestations and the microscopical features
of HPV-associated lesions vary with the anatomical site
affected and with the genotype of the HPV [7]. The varia-
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bility of the clinical and microscopical appearances and
the course of HPV infection are governed by the complex
interactions between the specific HPV genotype, viral
genetic variables, host immune response and the pheno-
type of the infected epithelial cell against a background of
differing environments and life-styles [9].
Immunosuppressed people are at significantly greater risk
of developing HPV infection and of experiencing a more
aggressive course of infection than immunocompetent
people. The immune system plays an important rôle in
controlling HPV infection [2,10], but since the intracellu-
lar HPV is shielded from the host immune surveillance
until the virus has been sufficiently amplified or the
infected keratinocytes exfoliate and disintegrate, the
immune response remains relatively low-level compared
to the immune response to viruses that are not confined
to epithelial cells [10,11].
More than 100 types of HPV have been identified, differ-
ing in the regulatory sequences and coding potential of
their genomes [9,10,12]. Because of the unequivocal
implication of HPV in the aetiopathogenesis of uterine
cervical squamous cell carcinoma (SCC), HPV types in
this context have been well studied and categorized into
low-risk and high-risk types according to their potential
for causing SCC [13]. Examples of low-risk HPV geno-
types are HPV-6, 11, 42, 43, 44 and of high-risk HPV gen-
otypes are HPV-16, 18, 31, 33, 35, 45, 51, 52, 56, 58 and
59 [6]. Distinct clinical manifestations are associated with
specific HPV genotypes [2,6,13-18] (Table 1).
In a small minority of women with persistent vulvo-vagi-
nal infection with high-risk HPV genotypes, cervical SCC
may develop as long as 12-15 years after the initial infec-
tion [12]. High-risk HPV genotypes, in particular HPV-16,
have also been implicated in the development of oral and
oropharyngeal SCC [14,15,19-24].
Low-risk HPV genotypes only rarely have been implicated
in malignant transformation [6]. In the mouth, low-risk
HPV infection is associated with a variety of benign
lesions including squamous cell papilloma, verruca vul-
garis (common wart), condyloma acuminatum and focal
epithelial hyperplasia (Heck disease), but can also be
detected in potentially malignant epithelial lesions such
as leukoplakia and erythroplakia [25,26].
High-risk HPV genotypes, in particular HPV-16 and -18
are prevalent in potentially malignant oral epithelial
lesions [27-29] and in oral SCC [30,31]; but the cells of
these lesions typically show low viral load, infrequent
viral integration into the cellular genome, and the trans-
formed cells seldom contain active transcriptional E6/E7
mRNA [31-33].
HPV Genome Organization and the Function of 
some of the HPV Gene Proteins
All types of HPV have the same general organization of
the genome: double-stranded circular DNA that carries
early (E) open reading frames (ORFs) encoding for non-
structural regulatory proteins, and late (L) ORFs encoding
for capsid proteins. Noncoding upstream regulatory
Table 1: HPV genotypes and their associated diseases.
Diseases and anatomical sites HPV genotype References
1. Benign oral lesions
1.1 Oral squamous cell papilloma HPV types 6 and 11 [16,17]
1.2 Veruca vulgaris (common wart) HPV types 1, 2, 4, 7 and 57 [16,17]
1.3 Condyloma acuminatum HPV types 2, 6, 11 (and less frequently HPV types 16, 18, 31, 33 and 35 [2,16-18]
1.4 Focal epithelial hyperplasia (Heck disease) HPV types 13 and 32 [2,16-18]
2. Potentially malignant oral lesions
2.1 Leukoplakia HPV types 16 and 18 [27-29]
HPV types 6 and 11 [25,28]
2.2 Erythroplakia HPV types 6, 11, 18, 31 and 33 [25,28]
3. Oral and oropharyngeal squamous cell carcinoma HPV types 16 and 18 [14-18]
4. Recurrent respiratory papillomatosis HPV types 6 and 11 [2,16-18]
5. Anogenital
5.1 Condyloma acuminata HPV types 6 and 11 [2,13]
5.2 Intraepithelial neoplasia
5.2.1 Low-grade HPV types 6 and 11 (less frequently HPV types 16, 18, 31, 33, 35) [2,13]
5.2.2 High-grade HPV types 16 and 18 (less frequently HPV types 6, 11, 31, 35) [2,13]
5.3 Squamous cell carcinoma HPV types 16 and 18 (less frequently 31, 33, 35, 39, 45, 51, 52, 58) [2,6,13]
6. Cutanous
6.1 Common warts HPV types 1 and 2 [2]
6.2 Flat warts HPV types 3 and 10 [2]Infectious Agents and Cancer 2009, 4:16 http://www.infectagentscancer.com/content/4/1/16
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region (URR) encompassing the origin of replication, the
E6/E7 gene promoter, and enhancers and silencers, is
located between the early and the late regions (Figure 1)
[2,3].
Early ORFs encode for E1, E2, E4, E5, E6 and E7 proteins.
E1 and E2 proteins bind to viral origin of replication,
recruit cellular proteins that mediate viral DNA replica-
tion, and regulate viral gene expression [3,7]. E1 and E2
are also responsible for the maintenance of viral DNA as
an episome during initial HPV infection, and also during
latent infection in the basal cell layer [3,10,34]. E2 facili-
tates the segregation of the HPV genome during cell divi-
sion resulting in the distribution of HPV DNA into
daughter cells [10,34]; and is involved in the packaging of
HPV DNA and in the promotion of virion assembly. Fur-
thermore, E2 has the capacity to repress the activity of E6/
E7 promoter [34].
The integration of HPV DNA within the cellular genome
that is evident in some HPV-associated malignancies dis-
rupts the E2 ORF leading to loss of E2 repressing function
[35], thus permitting free transactivation of E6/E7 pro-
moter by cellular transcription factors [2,11] and possibly
by other factors such as nutritional agents, resulting in the
increased expression of E6 and E7 oncoproteins [34].
E3 ORF does not encode for proteins [2]. The function of
E4 and E5 HPV proteins is not completely known [3]. E4
protein is assumed to modulate HPV DNA amplification
and structural gene expression [10,34]. E5 protein partici-
pates in HPV DNA amplification. It is also associated with
down-regulation of gap junction intercellular communi-
cations, with expression of major histocompatibility com-
plex (MHC) class 1 molecules, and with activation of
growth factor receptors. Thus E5 protein has the capacity
to promote immune evasion [34,36].
Little is known about the action of E6 and E7 proteins of
low-risk HPV genotypes during latent and subclinical
HPV infection [2,3]. During productive HPV infection
high- and low-risk HPV E6 and E7 facilitate the mainte-
nance of the viral episome in suprabasal matured epithe-
lial cells [3]. E6 and E7 also play an important rôle in the
increased cell proliferation and the extended cell survival
of HPV-associated malignancies, by altering the cell cycle
regulatory factors [36,37]. E6 of high-risk HPV can induce
ubiquitin-mediated degradation of p53 tumour suppres-
sor protein [38,39]; and E7 of high-risk HPV genotypes
can bind to and inactivate the Rb suppressor gene and
other cellular proteins associated with cell cycle regulation
[39,40]. Consequently E6 and E7 of high-risk HPV geno-
types are instrumental in the pathogenesis of HPV-associ-
ated malignancies.
E6 and E7 of low-risk HPV probably play a rôle in the
pathogenesis of HPV-associated benign tumours and only
rarely are implicated in malignant transformation. It is
The circular organization of HPV DNA episome (adapted from references [2,10,22]) Figure 1
The circular organization of HPV DNA episome (adapted from references [2,10,22]).
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unclear what properties E6 and E7 of high-risk HPV geno-
types possess that the E6 and E7 of low-risk HPV geno-
types do not possess, that enable them to induce
malignant transformation of some epithelial cells infected
with high-risk HPV. One possibility is that E6 and E7 pro-
teins of high-risk HPV genotypes have a greater affinity for
the regulatory factors of the cell cycle, thus causing an
exaggerated dysregulation of mechanisms of cell growth
and of cell survival [2].
E6 and E7 are not expressed in cells of the basal layer with
low-risk HPV infection [2], and it is uncertain whether E6
and E7 oncoproteins of high-risk HPV genotypes are
expressed in basal cells during productive HPV infection
that does not give rise to malignant changes [10].
In high-risk HPV infection associated with intraepithelial
neoplasia or with invasive malignancy, E6 and E7 onco-
proteins are expressed in progenitor basal layer keratinoc-
ytes mediating basal cell proliferation and genomic
instability, making the infected cells susceptible to addi-
tional genetic alterations leading to cell transformation
and possibly to the subsequent development of SCC [35].
The biological effects induced by E6 and E7 of high-risk
HPV have been investigated in great detail. Little is known
about the biological properties and mode of action of E6
and E7 proteins of low-risk HPV genotypes [2].
E8 ORF has been identified only in bovine papillomavirus
[2]. L1 ORF encodes for major capsid protein and L2 ORF
for minor capsid protein [2]. L1 protein is expressed after
L2 protein in the viral replication cycle and mediates pack-
aging of HPV particles and virion assembly. L2 protein
interacts with E2 protein, facilitates the transport of L1
protein to the nucleus, and plays a role in the encapsula-
tion of viral DNA [10].
Epithelial Cell Proliferation and Maturation
The cells of the epithelium comprise two populations of
cells, the progenitor and the maturing. The former cells
are based in the basal and parabasal layers, have the
capacity to proliferate by mitotic division following which
some of the newly divided (amplifying) cells enter a mat-
uration process and gradually rise through the several
morphologically distinct cell layers to the surface, while
some remain to maintain the integrity of the basal layer.
In the mouth this process of maturation follows two main
patterns: keratinization, and non-keratinization [41].
Some authors refer to this process of maturation as differ-
entiation [2,3,10]. The authors of this paper prefer the
term maturation, as we think that the term differentiation
should be restricted to the development of specific popu-
lations of stem cells arising from the zygote that form par-
ticular cell compartments and possess distinct
characteristics such as function, shape and rate of turnover
[42].
Whether the cells that give rise to new progenitor cells and
those that give rise to cells destined to go through the
process of maturation are in fact distinct sub-populations,
or whether the fates of all cells resulting from mitoses in
the basal cell layer are determined by changing local
microenvironment, is uncertain.
HPV Cycle as it Relates to Epithelial Cell 
Maturation
The HPV cycle is influenced by the stage of maturation of
the infected keratinocyte in the squamous epithelium
[2,3,10]. The production of virions is restricted to mature
suprabasal epithelial cells where all the virus genes are
expressed [43]. Why HPV virions can be produced only by
suprabasal postmitotic infected epithelial cells is not
known [3].
HPV infection starts when the viruses enter epithelial
basal cells which are referred to as the target cells of the
virus [10,44]. Once inside the target cell, the viral DNA
undergoes uncoating and is transported to the nucleus
where the HPV genome will persist as multiple episomal
copies [10]. In HPV-infected basal cells, E1 and E2 pro-
teins are expressed and they regulate early viral DNA tran-
scription from the early promoter prior to production of
virions. When expression of E2 is more pronounced, E2
represses viral DNA replication by blocking cellular tran-
scription factors, thus controlling the number of HPV
DNA copies in the basal cell by a process analogous to
negative feedback [3]. A stable number of about twenty to
one hundred HPV DNA copies per cell is regulated by E1
and E2 viral proteins in the basal cells for as long as the
infection persists [3].
In cases of high-risk HPV infection, E6 and E7 may also be
expressed in HPV-infected basal cells, and the epithelium
may then enter a proliferative phase characterized by an
increasing number of HPV-infected basal cells [10], cul-
minating in intraepithelial or invasive neoplasm.
Why HPV can infect basal cells in the first instance but not
the cells of other epithelial layers is not known; but this is
probably related to specific surface receptors confined to
basal cells [2]. The attachment of the virus to the basal cell
membrane receptor may be mediated by heparin sul-
phate, and the bound virus enters the cell by a slow proc-
ess of endocytosis [10]. As the basal cells divide, E2
mediates distribution of some HPV DNA copies to daugh-
ter cells, while some copies remain in the progenitor cells,
in both cases, as episomes [35].Infectious Agents and Cancer 2009, 4:16 http://www.infectagentscancer.com/content/4/1/16
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In latent HPV infection the affected epithelium looks both
clinically and histologically normal because the gene
expression of the latent genes is restricted to E1 and E2
[10]. The virus can remain latent for long periods, can be
cleared by the immune system, or can be activated and
initiate productive infection [35].
As the epithelial cells mature, the HPV cycle progresses to
productive replication [10,43]. In HPV infected epithe-
lium where virions are being produced the matured epi-
thelial cells express HPV E6 and E7 proteins in the
suprabasal layers. E6 prevents apoptosis that normally
occurs in response to viral infection; and E7 has the capac-
ity to overcome the physiological blockade of DNA syn-
thesis at the G1/S phase of the cell cycle in these post-
mitotic cells. Thus E7 activates the cellular DNA replica-
tion mechanism allowing matured epithelial cells to re-
enter the S phase of the cell cycle, and although this does
not usually result in full replication of the cellular genome
it makes the cellular replication machinery available for
viral DNA replication [3,35,37,45].
Multiplication of the viral genome, synthesis of early gene
proteins (E2, E4, E6, E7) and late gene proteins (L1, L2),
assembly of virions, and release of virions from exfoliated
epithelial cells occur at progressive stages of maturation of
postmitotic HPV-infected epithelial cells. It is suggested
that specific cellular factors associated with epithelial cell
maturation activate late viral promoter located within E7
ORF resulting in expression of high levels of E1 and E2
viral replication proteins which activate late viral gene
expression. This increase in E1 and E2 expression leads to
HPV amplification resulting in an increase in viral
genome numbers parallel with the stages of epithelial cell
maturation. Eventually, mediated by L1 and L2 proteins,
the virus escapes from the shedding epithelial cells
[10,39].
Unlike the early promoter, the late promoter is not sup-
pressed by high levels of E2 [3]. The amplification of HPV
genome in the maturing epithelium is modulated by E4
and E5 proteins, and E6 and E7 proteins ensure the main-
tenance of the HPV genome as a stable replicating epi-
some. As outlined above, under certain circumstances E6
and E7 have the capacity to stimulate suprabasal postmi-
totic cells to re-enter the S-phase of the cell cycle resulting
in the development of proliferative epithelial lesions [3].
However, during subclinical HPV infection, although viral
production continues, for as yet unknown reasons, the
ability of E6/E7 to mediate the re-entry of suprabasal post-
mitotic epithelial cells at the S phase of the cell cycle is
limited, suprabasal proliferation of epithelial cells does
not occur, and proliferative epithelial lesions do not
develop [10]. In some instances, normal appearing epi-
thelial cells with subclinical infection may be adjacent to
the HPV-induced lesion [7].
HPV-induced benign lesions are characterized by prolifer-
ation of cells of all epithelial layers [46]. This proliferation
is most probably mediated by E6/E7 proteins of mainly
low-risk HPV. The proliferation manifests microscopically
as acanthosis, hyperkeratosis and parakeratosis [7,46].
Koilocytes in the upper layers of the epithelium are evi-
dent [7].
Microscopic examination of high-risk HPV-induced high-
grade intraepithelial neoplasia shows greatly increased
numbers of mitotic figures and features of cellular atypia,
and extension of these multiplying atypical cells into the
suprabasal layer of the epithelium as the outcome of
expression of high-risk HPV E6/E7 oncoproteins in the
basal cells [35].
HPV-Associated Oral Benign, Potentially 
Malignant and Malignant Oral Lesions
In persons who have been exposed to HPV, several HPV
types have been detected in their apparently normal oral
mucosa, and in certain specific benign, potentially malig-
nant and malignant oral lesions, in the aetiology of which
they appear to be implicated. In infected persons, in clin-
ically and histologically normal looking oral mucosa, the
HPV exists in a latent form as a low-copy number episome
in basal epithelial cells [17]. In HPV-associated lesions,
there is a substantial increase in intraepithelial HPV DNA
copy-numbers [39].
Oral HPV infection is acquired primarily by sexual trans-
mission, or less frequently by non-sexual direct transmis-
sion, by mother to child transmission or by
autoinoculation. Persons who practise oral-genital sex,
those who have had a number of sexual partners, and
those who are immunocompromised are at greater risk of
acquiring oral HPV infection [4,5,14,47-49].
HPV-associated benign oral lesions
Many of the low-risk genotypes and uncommonly, high-
risk types have been found in the HPV-associated benign
oral lesions, oral squamous cell papilloma, verruca vul-
garis (common wart), condyloma acuminatum and focal
epithelial hyperplasia (Heck disease) [17,18,50,51], col-
lectively termed oral warts. The four types of oral warts
share the characteristics of being exophytic, sessile or
pedunculated, or of having filiform or 'cauliflower'-like
surface. The lesions can be single, multiple, or clustered
[17,49,52], are usually painless and chronic, and occa-
sionally regress spontaneously [53].Infectious Agents and Cancer 2009, 4:16 http://www.infectagentscancer.com/content/4/1/16
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Although certain HPV types have been implicated in the
aetiology of the different oral warts, there is considerable
overlapping of viral types among the lesions, and not
infrequently viral types not generally associated with a
particular lesion, can be identified. Therefore viral typing,
which one would expect to be a diagnostic differentiator
of oral warts cannot always be relied upon.
HPV-associated potentially premalignant and malignant 
lesions
The reported rates of HPV DNA detection in potentially
malignant (leukoplakia, erythroplakia) and malignant
(squamous cell carcinoma) oral lesions range from 0 to
100% [54,55]. This extreme variation is owing to differ-
ences in ethnicity, geographic locations and sample size of
the subjects examined, and to variations in methods of
detection of HPV.
High-risk HPV genotypes, in particular HPV-16 and -18,
have been reported to be the most prevalent in oral squa-
mous cell carcinoma [30,31,56-58], and HPV-16 in oral
leukoplakia including proliferative verucous leukoplakia
[27,28]. However, there are reports that low-risk rather
than high-risk HPV genotypes are more prevalent in oral
leukoplakia [23,25]; and co-infection with several differ-
ent HPV-genotypes is not uncommon [28,59].
In a meta-analysis of data from 94 studies of 4580 speci-
mens, Miller and Johnston (2001) determined that the
likelihood of HPV to be detected in normal oral mucosa,
in non-dysplastic leukoplakia, in dysplastic oral leukopla-
kia and in other precancerous intra-epithelial oral neo-
plasms, and in oral squamous cell carcinoma is likely to
be about 10%, 20%, 26% and 47% respectively. This sug-
gests that HPV may have an oncogenic or a co-oncogenic
rôle in some HPV-cytopositive potentially malignant and
malignant oral epithelial neoplasms [23].
With HPV-16 cytopostive oropharyngeal SCC as a model
of HPV-mediated epithelial cancerization, a causal associ-
ation between HPV and oral SCC is likely if the cells of
HPV-cytopositive oral SCC express transcriptionally active
E6/E7 mRNA, frequently demonstrate viral integration
within the cellular genome, show high viral load (> 1 copy
per cell), show unmutated p53 gene, reduced expression
of Rb proteins, overexpression of p16INK4A, and infrequent
loss of heterozygosity (LoH) at chromosomal loci 3p, 9p
and 17p [33,60-66].
As the cells of HPV-cytopositive oral squamous cell carci-
noma and potentially malignant lesions are typically
characterised by infrequent expression of transcriptionally
active E6/E7 mRNA, by infrequent viral integration within
the cellular genome, by low HPV viral load and by fre-
quent LoH at chromosomal loci 3p, 9p and 7p [32,33,66];
and as overexpression of p16INK4A, of p53 and of Rb pro-
teins is not unequivocally associated with the presence of
high-risk HPV DNA [31], there would appear to be only a
weak causal association between the HPV in the cells and
the process of malignant transformation.
It is possible that HPV super-infection of initially trans-
formed oral keratinocytes may promote progression of
transformation in an additive or synergistic manner,
through mechanisms as yet unknown [62], or that in
some HPV-cytopositive transformed keratinocytes that do
not express E6/E7 mRNA, E6/E7 oncoproteins have par-
ticipated in the initial stages of transformation but phased
out during later stages [67].
Although it is clear that there is some link between HPV
and potentially malignant and malignant epithelial oral
lesions, the precise rôle of the virus in the aetiopathogen-
esis of these oral lesions is unknown.
Summary
HPV is epitheliotropic, and it may be present in a latent
form, a subclinical form or in a form which in association
with other ill-defined factors can induce benign or malig-
nant epithelial neoplasms. Figure 2 summarizes the differ-
ent manifestations of HPV infection and the relationships
between latent, subclinical and clinical HPV infection.
While some viral proteins are expressed in HPV-infected
basal cells independently of the cell maturation process
regulating early viral DNA transcription from early pro-
motor prior to production of virions, the productive
phase of the viral cycle is dependent on specific cellular
factors associated with the progressive stages of matura-
tion of post-mitotic cells as the cells gradually rise trough
the layers of epithelium to the surface, and exfoliate.
Persistent high-risk HPV infection in a subset of subjects
with HPV-cytopositive oropharyngeal epithelium induces
genomic instability in these cells, making them suscepti-
ble to additional genetic alterations leading to cell trans-
formation and to subsequent development of squamous
cell carcinoma. In these oropharyngeal squamous cell car-
cinomas there is a causal association between HPV infec-
tion and the malignancy. In contrast, the nature of the
link between high-risk HPV genotypes and potentially
malignant and malignant oral epithelial lesions is not
known.
Low-risk HPV infection of oral epithelium is associated
with squamous cell papilloma, verruca vulgaris (common
wart), condyloma acuminatum and focal epithelial hyper-
plasia (Heck disease); and possibly with the potentiallyInfectious Agents and Cancer 2009, 4:16 http://www.infectagentscancer.com/content/4/1/16
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malignant oral epithelial lesions, leukoplakia and eryth-
roplakia.
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